Nexo Therapeutics, Inc.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2022 | $60 M | No. 1 | $50 to $250 million | equity, debt | SEC |
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Nexo Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2026).
SEC Form D · Mar 2026
The industry group it chose in its notices: Biotechnology.
SEC Form D · Mar 2026
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Nexo Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Andrew Phillips | Executive officer | Mar 2026 |
| Michael Kim | Executive officer | Sep 2024 |
| Ali Behbahani | Director | Mar 2026 |
| Andrew Phillips | Director | Mar 2026 |
| Carlo Rizzuto | Director | Mar 2026 |